Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
Frazier Life Sciences Management, L.P.
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$3.9B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
38
positionsALL retained default holdings for this (filer, period), including NULL-value ones
4
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
6
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
MIRUM PHARMACEUTICALS INC COMposition key pos:12357 · issuer key iss:1485 | add | +$173M | +884,563 | $537M | $709M | 6,795,121 | 7,679,684 | |
ERASCA INC COMposition key pos:12600 · issuer key iss:846 | add | +$315M | +1,945,752 | $84.6M | $399M | 22,729,436 | 24,675,188 | |
BRIDGEBIO PHARMA INC COMposition key pos:15468 · issuer key iss:427 | trim | −$15.1M | −97,418 | $271M | $256M | 3,545,557 | 3,448,139 | |
KRYSTAL BIOTECH INC COMposition key pos:17789 · issuer key iss:1307 | trim | +$3.9M | −7,153 | $120M | $124M | 488,460 | 481,307 | |
TREVI THERAPEUTICS INC COMposition key pos:18739 · issuer key iss:2160 | trim | −$9.9M | −319,862 | $128M | $119M | 10,259,409 | 9,939,547 | |
PALVELLA THERAPEUTICS INC NE COMposition key sid:sec:prov:306a1219dc3e80453ba2cb392e4281b0 · issuer key cusip6:697947 | add | +$34.4M | +160,000 | $75.6M | $110M | 722,400 | 882,400 | |
KALVISTA PHARMACEUTICALS INC COMposition key pos:10966 · issuer key cusip6:483497 | trim | +$18.5M | −78,759 | $81.4M | $99.9M | 5,039,867 | 4,961,108 | |
DISC MEDICINE INC COMposition key pos:13022 · issuer key iss:741 | add | −$13.4M | +94,852 | $100M | $86.6M | 1,260,000 | 1,354,852 | |
CYTOKINETICS INC COM NEWposition key pos:13331 · issuer key iss:700 | add | +$17.1M | +225,237 | $59.4M | $76.4M | 934,642 | 1,159,879 | |
REVOLUTION MEDICINES INC COMposition key pos:15541 · issuer key iss:1842 | trim | +$2.2M | −121,769 | $63.5M | $65.7M | 797,455 | 675,686 | |
SAVARA INC COMposition key sid:sec:prov:2bc6a25d40cf07124e3a03bdecf4a4df · issuer key cusip6:805111 | trim | −$6.4M | −141,449 | $59.5M | $53.1M | 9,862,301 | 9,720,852 | |
AGIOS PHARMACEUTICALS INC COMposition key pos:14037 · issuer key cusip6:00847X | trim | +$7.7M | −23,674 | $34.8M | $42.5M | 1,279,754 | 1,256,080 | |
BIOCRYST PHARMACEUTICALS INC COMposition key pos:15962 · issuer key iss:374 | new | +$38.2M | +4,009,240 | $0 | $38.2M | — | 4,009,240 | |
ACADIA PHARMACEUTICALS INC COMposition key pos:18889 · issuer key iss:56 | add | −$2.6M | +141,000 | $34.6M | $32.0M | 1,297,198 | 1,438,198 | |
ACLARIS THERAPEUTICS INC COMposition key sid:sec:prov:d6ea93a81ffbe77fbd59d8ff01875a57 · issuer key cusip6:00461U | new | +$18.5M | +4,925,374 | $0 | $18.5M | — | 4,925,374 | |
MONTE ROSA THERAPEUTICS INC COMposition key sid:sec:prov:3224bd4d4c1e7dd823e99e6304f866c2 · issuer key cusip6:61225M | new | +$16.5M | +1,000,000 | $0 | $16.5M | — | 1,000,000 | |
IMMUNOCORE HLDGS PLC ADSposition key pos:16434 · issuer key iss:1166 | add | +$1.3M | +100,000 | $13.4M | $14.6M | 384,782 | 484,782 | |
MANNKIND CORP COM NEWposition key sid:sec:prov:9318e51aacd9a6ead589f2a198b9f099 · issuer key cusip6:56400P | add | −$9.5M | +1,675,000 | $24.0M | $14.5M | 4,225,000 | 5,900,000 | |
ALLOGENE THERAPEUTICS INC COMposition key pos:13654 · issuer key cusip6:019770 | trim | +$4.0M | −72,082 | $5.3M | $9.3M | 3,868,750 | 3,796,668 | |
AUTOLUS THERAPEUTICS LTD SPON ADSposition key sid:sec:prov:0cba59ee844ea8b6e5b356f9157cdead · issuer key cusip6:05280R | trim | −$3.1M | −175,414 | $9.2M | $6.1M | 4,623,324 | 4,447,910 | |
XILIO THERAPEUTICS INC COMposition key sid:sec:prov:50b90ba597b540bfcb2c38228fbf9152 · issuer key cusip6:98422T | new | +$3.6M | +422,505 | $0 | $3.6M | — | 422,505 | |
| pos:13227 | exit‡e | −$51.0M | −378,300 | $51.0M | $0 | 378,300 | — | |
| pos:18617 | exit‡e | −$9.2M | −241,592 | $9.2M | $0 | 241,592 | — | |
| sid:sec:prov:0983c227d7f489fadce1abda0a417532 | exit‡e | −$33.3M | −983,333 | $33.3M | $0 | 983,333 | — | |
| sid:sec:prov:1e2859c0e2eb3d17b1bcb42459c1f71b | exit‡e | −$3.8M | −5,915,091 | $3.8M | $0 | 5,915,091 | — | |
| sid:sec:prov:652160e4f88d5e68e96c8504db5fee2d | exit‡e | −$4.9M | −521,000 | $4.9M | $0 | 521,000 | — | |
| sid:sec:prov:fc7c842ed91a7e3b374f2a94cbad8d9a | exit‡e | −$70.9M | −983,125 | $70.9M | $0 | 983,125 | — |
7 more changes below.
Mark-to-market only (no share change) · 17
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARESposition key pos:17285 · issuer key iss:2704 | no change | −$52.0M | 0 | $594M | $542M | 16,943,774 | 16,943,774 | |
ARCUTIS BIOTHERAPEUTICS INC COMposition key sid:sec:prov:fa36e00268ee3d6d74f8ff5697fdd99c · issuer key cusip6:03969K | no change | −$54.1M | 0 | $287M | $233M | 9,874,511 | 9,874,511 | |
MBX BIOSCIENCES INC COMposition key sid:sec:prov:1910147dd0682cb840152de5838d5484 · issuer key cusip6:55287L | no change | −$11.2M | 0 | $210M | $199M | 6,652,013 | 6,652,013 | |
PHATHOM PHARMACEUTICALS INC COMposition key sid:sec:prov:7715098c333bbe982e541f4b97bf5506 · issuer key cusip6:71722W | no change | −$68.3M | 0 | $207M | $139M | 12,466,489 | 12,466,489 | |
MAZE THERAPEUTICS INC COMposition key pos:16236 · issuer key iss:1445 | no change | −$52.9M | 0 | $189M | $136M | 4,567,274 | 4,567,274 | |
DYNE THERAPEUTICS INC COMposition key pos:14578 · issuer key iss:778 | no change | −$4.5M | 0 | $61.7M | $57.2M | 3,153,082 | 3,153,082 | |
TARSUS PHARMACEUTICALS INC COMposition key pos:11454 · issuer key iss:2092 | no change | −$8.5M | 0 | $59.7M | $51.1M | 728,644 | 728,644 | |
VOR BIOPHARMA INC COM NEWposition key sid:sec:prov:60242973181bde6041719c13381cdbb1 · issuer key cusip6:929033 | no change | +$12.1M | 0 | $33.3M | $45.4M | 2,543,939 | 2,543,939 | |
ZAI LAB LTD ADRposition key pos:14704 · issuer key cusip6:98887Q | no change | +$2.2M | 0 | $33.6M | $35.8M | 1,902,320 | 1,902,320 | |
AURA BIOSCIENCES INC COMposition key sid:sec:prov:d9ef490e51d912cfdcf16dffb423f2d5 · issuer key cusip6:05153U | no change | +$6.3M | 0 | $27.8M | $34.1M | 5,100,000 | 5,100,000 | |
ASCENDIS PHARMA A/S SPONSORED ADRposition key pos:16862 · issuer key iss:252 | no change | +$2.1M | 0 | $28.4M | $30.5M | 133,333 | 133,333 | |
LEXEO THERAPEUTICS INC COMposition key sid:sec:prov:bd4b862f6cf27f7bbb6f4d26443faaca · issuer key cusip6:52886X | no change | −$18.5M | 0 | $43.9M | $25.4M | 4,424,725 | 4,424,725 | |
ALKERMES PLC SHSposition key pos:16418 · issuer key iss:2418 | no change | +$5.2M | 0 | $19.6M | $24.8M | 700,647 | 700,647 | |
VALNEVA SE SPONSORED ADSposition key sid:sec:prov:d108e13f60d31b059c4e2b93d96b8387 · issuer key cusip6:92025Y | no change | −$5.9M | 0 | $20.2M | $14.3M | 2,291,666 | 2,291,666 | |
EVOLUS INC COMposition key sid:sec:prov:3c1bdde45f78766466db92da273259f5 · issuer key cusip6:30052C | no change | −$6.7M | 0 | $17.5M | $10.8M | 2,630,665 | 2,630,665 | |
NEWAMSTERDAM PHARMA COMPANY *W EXP 99/99/999position key pos:14719 · issuer key iss:2704 | no change | −$1.5M | 0 | $11.5M | $10.0M | 500,333 | 500,333 | |
IBIO INC COM NEWposition key sid:sec:prov:1da079c25df03f1597bca8fccb831a3d · issuer key cusip6:451033 | no change | −$58.6K | 0 | $3.8M | $3.7M | 1,953,467 | 1,953,467 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 95.6%above median 80.0%
- Concentration index
- 823 bpsabove median 446 bps
- Positions with value
- 38 / 38median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 95.6% · HHI (bps) ·§: 823integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 44
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open Frazier Life Sciences Management, L.P.'s 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–37 of 37 issuers · $3.9B disclosed value over 38 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | MIRMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MIRUM PHARMACEUTICALS INC MIRUM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $709M | 7,679,684 | — | 18.3% | — | |
| — | NAMSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEWAMSTERDAM PHARMA COMPANY | $552M | 17,444,107 | — | 14.2% | — | |
| — | ERASverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ERASCA INC ERASCA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $399M | 24,675,188 | — | 10.3% | — | |
| — | BBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIDGEBIO PHARMA INC BRIDGEBIO PHARMA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $256M | 3,448,139 | — | 6.6% | — | |
| — | — | ARCUTIS BIOTHERAPEUTICS INC ARCUTIS BIOTHERAPEUTICS INC · COM CUSIP 03969K108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $233M | 9,874,511 | — | 6.0% | — | |
| — | — | MBX BIOSCIENCES INC MBX BIOSCIENCES INC · COM CUSIP 55287L101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $199M | 6,652,013 | — | 5.1% | — | |
| — | — | PHATHOM PHARMACEUTICALS INC PHATHOM PHARMACEUTICALS INC · COM CUSIP 71722W107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $139M | 12,466,489 | — | 3.6% | — | |
| — | — | MAZE THERAPEUTICS INC MAZE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $136M | 4,567,274 | — | 3.5% | — | |
| — | KRYSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KRYSTAL BIOTECH INC KRYSTAL BIOTECH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $124M | 481,307 | — | 3.2% | — | |
| — | TRVIverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TREVI THERAPEUTICS INC TREVI THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $119M | 9,939,547 | — | 3.1% | — | |
| — | — | PALVELLA THERAPEUTICS INC NE PALVELLA THERAPEUTICS INC NE · COM CUSIP 697947109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $110M | 882,400 | — | 2.8% | — | |
| — | — | KALVISTA PHARMACEUTICALS INC KALVISTA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $99.9M | 4,961,108 | — | 2.6% | — | |
| — | IRONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DISC MEDICINE INC DISC MEDICINE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $86.6M | 1,354,852 | — | 2.2% | — | |
| — | CYTKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CYTOKINETICS INC CYTOKINETICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $76.4M | 1,159,879 | — | 2.0% | — | |
| — | RVMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVOLUTION MEDICINES INC REVOLUTION MEDICINES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $65.7M | 675,686 | — | 1.7% | — | |
| — | DYNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DYNE THERAPEUTICS INC DYNE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $57.2M | 3,153,082 | — | 1.5% | — | |
| — | — | SAVARA INC SAVARA INC · COM CUSIP 805111101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $53.1M | 9,720,852 | — | 1.4% | — | |
| — | TARSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TARSUS PHARMACEUTICALS INC TARSUS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $51.1M | 728,644 | — | 1.3% | — | |
| — | — | VOR BIOPHARMA INC VOR BIOPHARMA INC · COM NEW CUSIP 929033207 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $45.4M | 2,543,939 | — | 1.2% | — | |
| — | — | AGIOS PHARMACEUTICALS INC AGIOS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $42.5M | 1,256,080 | — | 1.1% | — | |
| — | BCRXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOCRYST PHARMACEUTICALS INC BIOCRYST PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.2M | 4,009,240 | — | 1.0% | — | |
| — | — | ZAI LAB LTD ZAI LAB LTD · ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $35.8M | 1,902,320 | — | 0.9% | — | |
| — | — | AURA BIOSCIENCES INC AURA BIOSCIENCES INC · COM CUSIP 05153U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.1M | 5,100,000 | — | 0.9% | — | |
| — | ACADverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ACADIA PHARMACEUTICALS INC ACADIA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $32.0M | 1,438,198 | — | 0.8% | — | |
| — | ASNDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ASCENDIS PHARMA A/S ASCENDIS PHARMA A/S · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $30.5M | 133,333 | — | 0.8% | — | |
| — | — | LEXEO THERAPEUTICS INC LEXEO THERAPEUTICS INC · COM CUSIP 52886X107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $25.4M | 4,424,725 | — | 0.7% | — | |
| — | ALKSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALKERMES PLC ALKERMES PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.8M | 700,647 | — | 0.6% | — | |
| — | — | ACLARIS THERAPEUTICS INC ACLARIS THERAPEUTICS INC · COM CUSIP 00461U105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.5M | 4,925,374 | — | 0.5% | — | |
| — | — | MONTE ROSA THERAPEUTICS INC MONTE ROSA THERAPEUTICS INC · COM CUSIP 61225M102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.5M | 1,000,000 | — | 0.4% | — | |
| — | IMCRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.6M | 484,782 | — | 0.4% | — | |
| — | — | MANNKIND CORP MANNKIND CORP · COM NEW CUSIP 56400P706 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.5M | 5,900,000 | — | 0.4% | — | |
| — | — | VALNEVA SE VALNEVA SE · SPONSORED ADS CUSIP 92025Y103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.3M | 2,291,666 | — | 0.4% | — | |
| — | — | EVOLUS INC EVOLUS INC · COM CUSIP 30052C107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.8M | 2,630,665 | — | 0.3% | — | |
| — | — | ALLOGENE THERAPEUTICS INC ALLOGENE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.3M | 3,796,668 | — | 0.2% | — | |
| — | — | AUTOLUS THERAPEUTICS LTD AUTOLUS THERAPEUTICS LTD · SPON ADS CUSIP 05280R100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.1M | 4,447,910 | — | 0.2% | — | |
| — | — | IBIO INC IBIO INC · COM NEW CUSIP 451033708 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.7M | 1,953,467 | — | 0.1% | — | |
| — | — | XILIO THERAPEUTICS INC XILIO THERAPEUTICS INC · COM CUSIP 98422T209 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.6M | 422,505 | — | 0.1% | — |
1–37 of 37 issuers · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).